OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) went higher by +5.116% to close at $ 0.452. The company exchanged total volume of 0 shares throughout course of last trade however it holds an average trading capacity of 479.37 thousand shares.
The company is trading above its 50-day moving averages of 0.421 and down from 200-day moving averages of 0.736. The firm has price to book ratio of 0.457 and its price to sale ratio was 0.724.
According to ZACKS data, different Brokerage Firms rated OGXI stock about their BUY, SELL or HOLD recommendations. 1 Week Ago, shares have been suggested as BUY from NA brokerage firms and recommended as Strong Buy by NA brokerage firms.NA brokerage firms have issued Sell rating for the company and Strong Sell rating was issued by NA brokerage firms.NA brokerage firms have rated the company as a Hold. The Corporation has average brokerage recommendation (ABR) of NA based on consensus of the brokerage firms issuing ratings.
The average true range of OncoGenex Pharmaceuticals, Inc.’s (OGXI) is recorded at 0.06 and the relative strength index of the stock stands 54.27. The stock price is going above to its 52 week low with 36.56% and lagging behind from its 52 week high with -83.86%. Analyst recommendation for this stock stands at 2.70. A look on the firm performance, its monthly performance is 29.33% and a quarterly performance of -17.95%. The stock price is trading downbeat from its 200 days moving average with -39.11% and up from 50 days moving average with 1.09%.
Globus Medical, Inc. (NYSE:GMED) dropped -0.66% and closed the trade at $ 20.95. The company recorded a trading capacity of 743.2 thousand shares below its three months average daily volume of 765.17 thousand shares. During the last trade, shares reached to high price of $21.09 and touched the low price of $20.81. The stock’s 50-day moving average is noted at $22.34 and its 200-day moving average is stands at $23.36.
Additionally, the company has a PE ratio of 17.17 and has EPS of 1.22. The company has market capitalization of $2.01B.
GMED stock has received ratings from many brokerage firms according to ZACKS. 1 Week Ago, shares have been rated as Buy from 0 brokerage firms and 3 brokerage firms say as Strong Buy. 1 brokerage firms have suggested Sell for the company. 8 brokerage firms have recommended as a Hold. Strong Sell rating was given by 0 brokerage firms. The Company has average brokerage recommendation (ABR) of 2.58 based on consensus of the ZACKS brokerage firms.
Globus Medical, Inc.’s (GMED) has price-to-cash ratio of 7.68 and price to sale ratio of 3.57. The company net profit margin is 21.20% and gross profit margin is 76.40%. A look on the firm performance, its monthly performance is -9.54% and a quarterly performance of -7.46%. The stock price is moving down from its 20 days moving average with -4.87% and isolated negatively from 50 days moving average with -6.89%.